Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.

Principal, Oliver Wyman Actuarial Consulting
Partner, Health Services, Oliver Wyman
Director, Oliver Wyman Health Innovation Center, Oliver Wyman

The next global trend in medicine could be among the many traditional remedies in Indonesia, Vietnam, and China.

Principal, Health and Life Sciences, Oliver Wyman

A discussion on how mega mergers affect consumers and how consolidation is driving the new future of healthcare.

Health and wellness is shaping consumerism’s future. As potentially industry-shaking partnerships evolve, who’s best positioned to conquer the market?

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Global Leader, Health and Life Sciences, Oliver Wyman
Managing Partner, Americas, Oliver Wyman

Insights in your inbox


Some of our 2017 healthcare predictions on value-based care, consumers, mergers, startups, and pharma came true, while others were less predictable.

Director, Marsh & McLennan Advantage, Healthcare

What's around the bend for healthcare venture capital in 2018? We talk Amazon, good and bad M&A, and hitting the investment peak.

Senior Managing Director, GE Ventures

How a “sticky” consumer experience could help control the drain of high-cost chronic disease drugs.

Partner, Health and Life Sciences, Oliver Wyman